SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Retained Earnings
SCI Pharmtech Inc
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Retained Earnings
NT$2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Retained Earnings
NT$2.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Retained Earnings
NT$2.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
22%
|
CAGR 10-Years
21%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Retained Earnings
NT$1.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Retained Earnings
NT$12.7B
|
CAGR 3-Years
95%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Retained Earnings
NT$3.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
17%
|
CAGR 10-Years
15%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Retained Earnings?
Retained Earnings
2B
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Retained Earnings amounts to 2B TWD.
What is SCI Pharmtech Inc's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
12%
Over the last year, the Retained Earnings growth was 24%. The average annual Retained Earnings growth rates for SCI Pharmtech Inc have been 24% over the past three years , 9% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet